Do you want to read an article? Please log in or register.
PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort
Genitourinary Cancer
Related content
Genitourinary Cancer
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma
Eur J Cancer
Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer RJ, Chevreau C, Tannir NM, Oudard S, McDermott DF, Laguerre B, Hammers HJ, Barthelemy P, Plimack ER, Borchiellini D, Gross-Goupil M, Jiang R, Lee CW, de Silva H, Rini BI, Escudier B, Albigès L
doi: 10.1016/j.ejca.2024.114048
Lung, Respiratory and Thoracic Cancer
Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Lung Cancer
Stares M, Doyle E, Chapple S, Raynes G, MacDonald J, Barrie C, Laird B, MacKean M, Philips I
doi: 10.1016/j.lungcan.2024.107497
Genitourinary Cancer
PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion
Front Oncol
El Saadany T, Lorch A, Milowsky MI, Vogl UM, Cathomas R
doi: 10.3389/fonc.2024.1427452
SPECIAL REPORT
Genitourinary Cancer
EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1
Genitourinary Cancer
Spontaneous regression of metastatic clear cell renal cell carcinoma: A report of a rare case and a review of the literature
Urol Case Rep
Mullasseril A, Lam AB, Mitta A, Morton D, McIntosh A, Patel S, Thai T, Annan A, Ayanambakkam A
doi: 10.1016/j.eucr.2024.102868
Lung, Respiratory and Thoracic Cancer
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
Lung Cancer
Miyakoshi J, Yoshida T, Kashima J, Shirasawa M, Torasawa M, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Shiraishi K, Kohno T, Yamamoto N, Yatabe Y, Suzuki T, Ohe Y
doi: 10.1016/j.lungcan.2024.107788
Gastrointestinal Cancer
Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience
Int J Cancer
Sewastjanow-Silva M, Kwiatkowski E, Yamashita K, Abdelhakeem A, Yoshimura K, Vicentini ER, Pizzi MP, Jin J, Fan Y, Zou G, Wang L, Yin F, Dhar SS, Blum Murphy M, Mares JE, Li JJ, Gan Q, Waters RE, Rogers JE, Ajani JA
doi: 10.1002/ijc.35090
COMMENTED
Genitourinary Cancer
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Ann Oncol
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ
doi: 10.1016/j.annonc.2024.07.727
Genitourinary Cancer
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Lancet
Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ
doi: 10.1016/S0140-6736(24)01758-6